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Abstract
Introduction
The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has
been a concern when treating men with lower urinary tract symptoms (LUTS) with antimus-
carinic drugs.
Materials and methods
In NEPTUNE (12-week, double-blind), men (45 years) with LUTS were randomized to
receive tamsulosin oral-controlled absorption system (TOCAS) 0.4 mg, fixed-dose combina-
tion (FDC) of solifenacin (Soli) 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or
placebo. In NEPTUNE II (40-week, open-label extension of NEPTUNE), continuing patients
received 4-week FDC Soli 6 mg + TOCAS, then FDC Soli 6 mg or 9 mg + TOCAS for the
remainder of the study, switchable every 3 months.
Results
Across both studies, 1208 men received1 dose of FDC Soli 6 mg or 9 mg + TOCAS for up
to 52 weeks; 1199 men completed NEPTUNE and 1066 received1 dose in NEPTUNE II.
In total, 13 men (1.1%; 95% CI, 0.6%–1.8%) reported a UR event while receiving FDC, eight
of which were AUR (0.7%; 95% CI, 0.3%–1.3%, incidence 7/1000 man-years). Six men
reported UR events while taking Soli 6 mg + TOCAS (three AUR), and seven men reported
a UR event while taking Soli 9 mg + TOCAS (five AUR). One man developed AUR while
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Conclusions
FDC Soli and TOCAS was associated with a low rate of UR and AUR in men with LUTS.
Introduction
‘Lower urinary tract symptoms’ (LUTS) is an umbrella term that encompasses a broad spec-
trum of urinary symptoms, including storage symptoms (e.g., urgency, increased daytime fre-
quency, nocturia), voiding symptoms (e.g., slow stream, hesitancy, intermittency, terminal
dribble), and post-micturition symptoms (feeling of incomplete bladder emptying and post-
micturition dribbling) [1]. Voiding symptoms can be effectively treated with α1-adrenoceptor
antagonists (α1-blockers), whereas storage symptoms respond well to muscarinic receptor
antagonists (antimuscarinics) [2, 3]. However, many patients have both storage and voiding
LUTS and may be undertreated for the storage component [4] because of a perceived increased
risk of acute urinary retention (AUR), defined as ‘a painful, palpable, or percussible bladder
when the patient is unable to pass any urine’ [1], with antimuscarinics [5].
Reported AUR rates in clinical trials with antimuscarinics and α1-blockers in men with
LUTS associated with benign prostatic hyperplasia (LUTS/BPH) vary between studies and
range from 0% to 1.9%, corresponding to an incidence rate of 0–78.2/1000 man-years [6]. The
majority of trials evaluating antimuscarinics and α1-blocker combination therapy in men with
LUTS/BPH are of short duration (12 weeks). The 12-week NEPTUNE [7] and 40-week NEP-
TUNE II [8] studies assessed men with storage and voiding LUTS/BPH treated with two fixed-
dose combinations (FDCs) of the antimuscarinic solifenacin (Soli) and an oral-controlled
absorption system formulation of the α1-blocker tamsulosin (TOCAS). To our knowledge,
these are the only clinical trials that have studied the combination of an antimuscarinic and an
α1-blocker for a period of up to 52 weeks. Thereby, the studies provide important new infor-
mation regarding the long-term efficacy and tolerability of combined use of antimuscarinics
and α1-blockers in men with LUTS. The aim of the current analysis was to evaluate the rate
and time of onset of UR and the incidence of AUR cases (defined as those cases of UR that
required catheterization) occurring over a period of up to 1 year. Furthermore, we assessed the
relationship between the development of AUR and several baseline characteristics of the NEP-
TUNE study population that are known risk factors.
Patients and methods
Patient characteristics and study results for the NEPTUNE studies have been published previ-
ously [7]. In brief, men aged45 years were eligible to enter the studies if they had a diagnosis
of LUTS/BPH for at least 3 months, a total International Prostate Symptom Score (IPSS)13,
2 urgency episodes/24 h with Patient Perception of Intensity of Urgency Scale (PPIUS) grade
3 or 4 (i.e., severe urgency or urgency incontinence), and8 micturitions/24 h, as well as an
ultrasound-estimated prostate volume <75 mL, a maximum urinary flow rate (Qmax) of 4.0–
12.0 mL/s, and a post-void residual (PVR) volume of150 mL.
The NEPTUNE study (ClinicalTrials.gov identifier: NCT01018511, https://clinicaltrials.
gov/ct2/show/NCT01018511?term=NCT01018511&rank=1) was a 12-week, randomized,
double-blind, placebo-controlled, phase 3 trial that investigated the efficacy and safety of a
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once-daily FDC of Soli 6 mg or 9 mg and TOCAS 0.4 mg [7]. Patients were randomized 1:1:1:1
using a computer-generated randomized list to receive TOCAS 0.4 mg monotherapy, FDC
Soli 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or placebo for 12 weeks. Patients
completing NEPTUNE had the option to continue into the 40-week, open-label NEPTUNE II
extension study (ClinicalTrials.gov identifier: NCT01021332, https://clinicaltrials.gov/ct2/
show/NCT01021332?term=NCT01021332&rank=1) in which patients received FDC Soli 6 mg
+ TOCAS 0.4 mg for 4 weeks and could then choose to remain on Soli 6 mg + TOCAS 0.4 mg
or increase their dose to Soli 9 mg + TOCAS 0.4 mg [8]. Patients were permitted to switch
between doses at each subsequent 3-monthly visit (Fig 1). Data on FDC treatment from the
NEPTUNE and NEPTUNE II studies have been combined to cover the period of potential
drug exposure of up to 52 weeks. The NEPTUNE studies were approved by independent ethics
committees and were conducted in accordance with the Declaration of Helsinki; written
informed consent was obtained from all patients.
The safety analysis set (SAF) included all patients who received1 dose of FDC in NEP-
TUNE and/or NEPTUNE II and who had any safety data reported after the first dose. Adverse
events (AEs) were coded using MedDRA (Version 12.1) preferred terms. All cases of AUR, a
subgroup of UR cases that required catheterization, were reported as serious AEs. No specific
definitions for UR were provided. Analyses were performed according to exposure to FDC (up
to 52 weeks).
The occurrence of AUR/UR during the 1-year treatment period is illustrated in cumulative
incidence plots. A Cox-regression model was used to evaluate whether specific patient and
baseline disease characteristics (i.e., prostate-specific antigen [PSA], prostate volume, Qmax,
total IPSS, PVR, bladder voiding efficiency [calculated as voided volume/(voided volume
+ PVR)], age) were associated with an increase in the risk of developing AUR/UR; Pearson
Fig 1. Study design of NEPTUNE and NEPTUNE II.
doi:10.1371/journal.pone.0170726.g001
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correlation coefficients were derived between all characteristics of interest to understand the
relationship between the potential risk factors. All 95% confidence intervals for proportions
were calculated using the exact method.
Results
Patient disposition
Of 1334 men randomized into NEPTUNE, 1328 received1 dose of study medication and
were included in the SAF, and 1199 completed the 12-week, double-blind study. A total of 1066
patients received1 dose of open-label FDC therapy. Of these, 960 patients (90.1%) completed
the 40-week extension study and 106 patients (9.9%) discontinued, mainly due to AEs (n = 43,
4.0%), withdrawal of consent (n = 23, 2.2%), or lack of efficacy (n = 19, 1.8%). In total, 1208
patients received1 dose of FDC therapy during NEPTUNE and/or NEPTUNE II [8].
Urinary retention rates in NEPTUNE and NEPTUNE II
During the placebo run-in period, four men experienced UR, three cases of which were AUR and
led to discontinuation from the study. Across both NEPTUNE and NEPTUNE II, 14 men experi-
enced episodes of UR: 13 of the 1208 men (1.1%; 95% CI, 0.6%–1.8%) who received FDC Soli 6
mg or 9 mg + TOCAS (Table 1) and one man who received TOCAS monotherapy. For 10 of the
13 patients experiencing UR while on FDC, the investigator judged the events to be possibly or
probably related to study medication. Of these 13 men, eight (0.7%; 95% CI, 0.3%–1.3%; inci-
dence 7/1000 man-years) developed AUR, four cases of which required hospitalization. Detailed
information about each individual who experienced UR or AUR can be found in Table 2.
Of the 14 men experiencing UR, eight experienced episodes during the 12-week, double-
blind NEPTUNE study (Table 1). Three men (0.9%) receiving FDC Soli 6 mg + TOCAS (one
AUR, 0.3%, corresponding to an incidence rate of 13/1000 man-years), four men (1.2%)
receiving FDC Soli 9 mg + TOCAS (three AUR, 0.9%, corresponding to an incidence rate of
40/1000 man-years), and one man (0.3%, corresponding to an incidence rate of 13/1000 man-
years) of the 326 men receiving TOCAS monotherapy experienced an event of AUR.
Additionally, six men experienced UR, four of which were AUR, during the 40-week, open-
label NEPTUNE II study. Three men experienced the event onset of UR (two of which were
AUR) while receiving FDC Soli 6 mg + TOCAS. Similarly, three men experienced the event
onset of UR (two of which were AUR) while receiving FDC Soli 9 mg + TOCAS (Table 1).
Two men who experienced UR in NEPTUNE continued into the NEPTUNE II extension
study and did not experience any further episodes. None of the men experiencing UR in NEP-
TUNE II had prior episodes in the 12-week double-blind NEPTUNE study.
FDC dose duration at onset of urinary retention
The duration of FDC exposure at the time of onset of UR varied considerably (median 77
days, range 6–347 days); however, the majority of patients developed UR within the first 4
months of treatment (9 of 13, 69.2%). Four men (30.8%) had UR after at least 4 months of
treatment, one on Soli 6 mg + TOCAS and three on Soli 9 mg + TOCAS. Cumulative inci-
dence plots for AUR and UR (Fig 2A and 2B) were developed to illustrate the timing of their
occurrence in relation to the duration of treatment with FDC Soli 6 mg or 9 mg + TOCAS.
Baseline risk factors for acute urinary retention
The mean baseline values for potential risk factors for AUR of patients with UR or AUR on
FDC Soli + TOCAS (NEPTUNE/NEPTUNE II) and of the total NEPTUNE SAF population
Incidence of urinary retention in NEPTUNE and NEPTUNE II studies
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are presented in S1 Table. As some of these risk factors were found to be highly correlated
with each other (S2 Table), a post-hoc Cox-regression model, assessing risk of developing UR
or AUR, was derived separately for each potential risk factor (Table 3). The results of the Cox-
regression analysis indicated that decreased bladder voiding efficiency (BVE) and increased
PSA concentration, PVR volume, and prostate volume at baseline were associated with an
increased risk of developing AUR and UR; other risk factors tested (i.e., Qmax, total IPSS, age)
did not show evidence for an increased risk of AUR or UR.
Although an association between prostate volume and increased AUR/UR was determined,
the overall rates of UR and AUR were low in all patients regardless of prostate volume. In the
12-week double-blind study, the AUR rates on the FDC of Soli 6 mg + TOCAS were 0% (0/
203) and 0.7% (1/134) for patients with a prostate volume of40 mL and>40 mL, respec-
tively. The AUR rates on the FDC of Soli 9 mg + TOCAS were 0.5% (1/185) and 1.4% (2/138)
for patients with a prostate volume of40 mL and >40 mL, respectively.
Discussion
Traditionally, the use of antimuscarinics in men with LUTS/BPH, benign prostatic enlarge-
ment, and/or benign prostatic obstruction has been limited owing to fears of AUR [3]. This
belief, however, has been questioned by a number of studies performed over the past decade
Table 1. Numbers of patients on FDC Soli + TOCAS treatment with urinary retention or AUR in NEPTUNE and NEPTUNE II.
Treatment arm Total
FDC Soli 6 mg + TOCAS FDC Soli 9 mg + TOCAS
NEPTUNE (12 weeks) (n = 337) (n = 324) (n = 661)
UR, n (%, [95% CI]) 3 (0.9, [0.2–2.6]) 4 (1.2, [0.3–3.1]) 7 (1.1, [0.4–2.2])
AURa, n (%, [95% CI]) 1 (0.3, [0.0–1.6])b 3 (0.9, [0.2–2.7])c 4 (0.6, [0.2–1.5])d
Dose at onset of adverse event Total
FDC Soli 6 mg +TOCASe FDC Soli 9 mg +TOCASe
NEPTUNE II (40 weeks) (n = 1066) (n = 1066)
UR, n (%, [95% CI]) 3 3 6 (0.6, [0.2–1.2])
AURa, n (%, [95% CI]) 2 2 4 (0.4, [0.1–1.0])
Dose at onset of adverse event Total
FDC Soli 6 mg +TOCASe FDC Soli 9 mg +TOCASe
Total (up to 52 weeks) (n = 1208) (n = 1208)
UR, n (%, [95% CI]) 6 7 13 (1.1, [0.6–1.8])
AURa, n (%, [95% CI]) 3 5 8 (0.7, [0.3–1.3])f
95% CIs were calculated using the exact method.
a AUR cases were a subgroup of UR cases that required catheterization.
b Incidence of 13/1000 man-years (95% CI, 6.9–22.2). Previously reported incidence rate of 0 man-years; difference is accounted for by the inclusion of an
AUR case deemed not related to study medication that was not included in the previous analysis [6].
c Incidence of 40/1000 man-years (95% CI, 27.7–53.3).
d Incidence of 26/1000 man-years (95% CI, 17.0–38.1). Previously reported incidence rate of 19 man-years; difference is accounted for by the inclusion of
an AUR case deemed not related to study medication that was not included in the previous analysis [6].
e Percentages and incidence per 1000 man-years cannot be calculated for the individual doses as patients did not use either FDC 6 mg or 9 mg for a whole
year; furthermore, patients selected their dose (i.e., were not randomized), so the two dose groups cannot be assumed to be comparable.
f Incidence of 7/1000 man-years (95% CI, 2.8–14.4).
Note: One additional patient on TOCAS experienced AUR during the 12-week double-blind period (0.3%; incidence of 13/1000 man-years). Abbreviations:
AUR, acute urinary retention; CI, confidence interval; FDC, fixed-dose combination; Soli, solifenacin; TOCAS, tamsulosin oral-controlled absorption system;
UR, urinary retention.
doi:10.1371/journal.pone.0170726.t001
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demonstrating promising efficacy and safety of combination therapy using antimuscarinics
and α1-blockers [5]. The vast majority of data are from short-term studies (12 weeks), even
though treatment with antimuscarinics and α1-blockers combination therapy is a long-term
option. NEPTUNE II, together with NEPTUNE, is the only long-term study to assess the effi-
cacy and safety of 52 weeks of treatment with antimuscarinic and α1-blocker combination
therapy. Patients with storage and voiding LUTS, Qmax <12 mL/s, PVR volume150 mL, and
prostate volume <75 mL were eligible for inclusion. We consider that these patients are typical
candidates for combination therapy in routine clinical practice.
In NEPTUNE and NEPTUNE II, treatment with FDC Soli + TOCAS therapy for up to 52
weeks was associated with low rates of UR (1.1%) and AUR (0.7%, corresponding to an inci-
dence of 7/1000 man-years). Most cases occurred within the first 4 months after treatment ini-
tiation, and only one patient experienced UR after this period with the now-approved FDC
dosage (Soli 6 mg + TOCAS 0.4 mg). These results are in agreement with those of The Health
Table 2. Summary of patients on FDC Soli + TOCAS treatment with UR/AUR in NEPTUNE and NEPTUNE II, listed in chronological order of
appearance.
Days on FDC
at onset of
AE
FDC dose at
onset of AE
(mg)
AUR/
URa
Discontinued
study
Patient age
(years)
Total IPSS at
baseline
PVR volume at
baseline (mL)
Qmax at
baseline (mL/
s)
Prostate volume
at baseline (mL)
PSA
(ng/mL)
NEPTUNE (double-blind FDC Soli + TOCAS)
6 9 AUR No 72 14 28 9.4 74 2.8
12 9 AUR No 67 21 50 9.8 54 1.1
24 9 AUR Yes
22 6 AUR No 62 20 148 7.0 48 5.7
31 6 UR Yes 54 24 122 5.2 15 0.7
39 9 AUR Yes 75 16 15 7.8 35 4.3
53 9 UR No 68 17 134 10.6 24 2.2
77 6 UR No 66 22 75 7.9 46 1.4
NEPTUNE II (open-label FDC Soli + TOCAS)
106 6b AUR Yes 79 15 33 6.3 33 4.5
117 6c UR Yes 67 29 74 6.4 18 2.4
191d 9e UR No 58 18 48 7.0 65 5.2
194 6e AUR Yes 63 15 52 9.0 55 4.9
254f,g 9e AUR No 67 27 50 7.6 71 5.3
347h 9b AUR Yes 64 18 103 9.5 56 10.5
a AUR cases were a subgroup of UR cases that required catheterization.
b Treatment received in the NEPTUNE trial was FDC Soli 6 mg + TOCAS.
c Treatment received in the NEPTUNE trial was placebo.
d Patient increased to FDC Soli 9 mg + TOCAS for 67 days prior to onset.
e Treatment received in the NEPTUNE trial was TOCAS.
f Patient increased to FDC Soli 9 mg + TOCAS for 141 days prior to onset.
g High alcohol consumption noted the evening before UR onset.
h Patient increased to FDC Soli 9 mg + TOCAS for 149 days prior to onset.
Note: One additional patient on TOCAS experienced AUR during the 12-week double-blind period. The patient was hospitalized for osteoarthritis and later
hip arthroplasty; 2 days after hip arthroplasty, he developed UR. The patient did not discontinue the trial. Age: 64 years; total IPSS at baseline: 30; PVR
volume: 87 mL; Qmax: 6.2 mL/s; baseline prostate volume: 25 mL; PSA concentration: 0.3 ng/mL.
Abbreviations: AE, adverse event; AUR, acute urinary retention; FDC, fixed-dose combination; IPSS, International Prostate Symptom Score; PSA,
prostate-specific antigen; PVR, post-void residual; Qmax, maximum urinary flow rate; TOCAS, tamsulosin oral-controlled absorption system; UR, urinary
retention.
doi:10.1371/journal.pone.0170726.t002
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Improvement Network (THIN) database analysis, which reported the incidence of AUR in
men treated with oral antimuscarinics. This analysis found that the relative risk of AUR was
highest in early treatment (first 30 days) and lowered with time [9]. Consequently, patients at
risk for UR should be initially treated with caution and counselled for the symptoms and signs
of UR [10]. The long-term incidence of AUR on the FDC Soli 6 mg + TOCAS dose cannot be
calculated owing to the permitted dose changes during the 40-week open-label period; how-
ever, the total incidence in the patient population studied was low (7/1000 man-years) despite
the inclusion of cases reported while on the higher Soli 9 mg + TOCAS dose.
Rates of UR and AUR were similarly low during the first 12 weeks of the double-blind NEP-
TUNE study. Events of UR were reported in only 7 of 661 patients receiving FDC: three events
(0.9%) occurred with FDC 6 mg and four events (1.2%) occurred with FDC 9 mg. Four of
Fig 2. Cumulative Incidence of AUR (A) and UR (B) with FDC Soli 6 mg or 9 mg + TOCAS. (A) Acute
urinary retention. (B) Urinary retention. Black markers indicate 6 mg FDC dose at time of AUR/UR onset;
orange markers indicate 9 mg FDC dose at time of AUR/UR onset. AUR cases were a subgroup of UR cases
that required catheterization. Abbreviation: FDC, fixed-dose combination.
doi:10.1371/journal.pone.0170726.g002
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these UR events were AUR: one (0.3%, incidence 13/1000 man-years) occurred with FDC 6
mg and three (0.9%, incidence 40/1000 man-years) occurred with FDC 9 mg. These data are
consistent with previously published AUR rates and incidences for treatment with Soli
+ TOCAS [6, 11–13]. The AUR rates reported here are also consistent with other 12-week
studies evaluating tolterodine (another antimuscarinic) in combination with tamsulosin in
men with LUTS (0–0.9%) [14–16]. The AUR incidence in the NEPTUNE studies, regardless of
FDC dose, is also in the same range as the incidence of AUR reported for the general, symp-
tomatic, but untreated male LUTS population (18.3–35.9/1000 man-years) [6]. However, it
should be noted that inclusion and exclusion criteria varied between different clinical trials,
and thus populations are likely to have different propensities for UR.
Rates of UR and AUR in the NEPTUNE and NEPTUNE II studies may have been affected
by the inclusion and exclusion criteria: for example, patients with a PVR>150 mL were
excluded from the study, potentially lowering the overall risk of retention in this population.
In most other studies with antimuscarinics, baseline PVR volume was also restricted, typically
to200 mL. Thus, additional research would be required to comment on the use of combina-
tion therapy in men with higher baseline PVR volumes. Despite the exclusion of patients with
a prostate volume75 mL at baseline, mean/median prostate volume at baseline was 38.1/36.0
mL (range: 9–74 mL), which is comparable with patients investigated in the Medical Therapy
of Prostatic Symptoms (MTOPS) study (mean prostate volume of 36.3 mL [17]), indicating
that prostate volume was clearly increased for the majority of patients in this study, although
not typical for patients with LUTS/BPH.
A number of known risk factors for UR, as described in the MTOPS and Olmsted County
studies [17, 18], were present in the total NEPTUNE population at baseline, suggesting a pro-
pensity for UR in this population. While age and total IPSS were not shown to be associated
with risk for AUR, decreased BVE, and increased PSA, PVR, and prostate volume at baseline
were significantly associated with increasing risk of developing AUR/UR by cox-regression
analysis. Although more men with prostate volume >40 mL experienced AUR than men
whose baseline prostate volume was40 mL, the overall rate of AUR across the entire study
was low. As the low rates of AUR may impact the ability to accurately assess risk factors, the
results of this post-hoc analysis should therefore be interpreted with caution.
Table 3. Risk of developing AUR/UR by potential risk factors.
AUR* UR‡
Hazard Ratio 95% CI P-value Hazard Ratio 95% CI P-value
Age, years 1.05 0.94–1.16 0.40 1.02 0.94–1.12 0.62
Prostate volume, mL 1.08 1.02–1.13 0.004 1.04 1.00–1.08 0.048
Qmax, mL/s 0.85 0.60–1.21 0.36 0.78 0.59–1.03 0.08
Total IPSS 0.97 0.80–1.17 0.74 1.05 0.91–1.20 0.50
PSA concentration, ng/mL 1.41 1.16–1.71 <0.001 1.37 1.15–1.63 <0.001
PVR volume, mL 1.02 1.00–1.03 0.06 1.02 1.01–1.04 <0.001
BVE, % 0.94 0.90–0.99 0.03 0.93 0.89–0.97 <0.001
*Total subjects (N = 1202), censored (n = 1194)
‡Total subjects (N = 1202), censored (n = 1189).
Abbreviations: BVE, bladder voiding efficiency; CI, confidence interval; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen; PVR,
post-void residual; Qmax, maximum urinary flow rate.
Bold indicates statistical significance (P<0.05).
doi:10.1371/journal.pone.0170726.t003
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Following this clinical trial program, the FDC tablet of Soli 6 mg + TOCAS 0.4 mg has been
registered in 42 countries (Vesomni™ or Urizia™), in most cases for the treatment of moderate
to severe storage (urgency, increased micturition frequency) and voiding LUTS associated
with BPH in men who are not adequately responding to treatment with monotherapy. Regis-
tration procedures in other countries are ongoing.
Conclusions
Results from the NEPTUNE and NEPTUNE II studies suggest that treatment for up to 52
weeks with an FDC tablet containing Soli 6 mg or 9 mg with TOCAS 0.4 mg was well tolerated
and associated with low rates of UR and AUR in men with LUTS. The overall incidence of UR
was low, occurring in only 13 of 1208 patients (1.1%) receiving FDC Soli + TOCAS in either
NEPTUNE or NEPTUNE II, with eight of those patients (0.7%, incidence 7/1000 man-years)
requiring catheterization (AUR). Decreased BVE and increased PSA, PVR, and prostate vol-
ume at baseline were associated with an increased risk of developing AUR/UR. However, it
should be noted that the low rates of AUR/UR observed in this study limit the accuracy of risk
assessment. Most cases occurred within 4 months of treatment initiation, suggesting no
increase in the risk of AUR with long-term treatment compared with 12 weeks of treatment.
Supporting information
S1 Table. Mean baseline characteristics of patients with AUR/UR on FDC Soli + TOCAS
(NEPTUNE/NEPTUNE II) and the total NEPTUNE safety analysis set population.
(DOCX)
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